Bihua Chen
CIK 1599214 · Chairperson and CEO · last filed 2026-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$604.43M
Companies
22
Total Filings
45
Lifetime Open-Market Net
$446.78M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BBOT | Director | 1,905,046 | $8.59 | $16.36M | $0 | 3 | 2026-07-06 |
| HLXC | Chairperson and CEO | 497,500 | $10.56 | $5.25M | $16.00M | 2 | 2026-01-28 |
| EYPT | 10%+ Owner | 8,265,000 | $11.96 | $98.85M | $234.19M | 5 | 2025-12-08 |
| MLTX | 10%+ Owner | 1,994,173 | $18.71 | $37.31M | -$154.25M | 6 | 2025-10-01 |
| OKUR | 0 | $3.95 | $0 | -$20.18M | 1 | 2025-05-19 | |
| AARD | 800,189 | $6.42 | $5.14M | $6.00M | 1 | 2025-02-19 | |
| BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | CEO and Chairperson | — | $9.90 | — | $0 | 1 | 2025-02-10 |
| DRUG | 10%+ Owner | 1,059,331 | $71.96 | $76.23M | $17.70M | 2 | 2024-11-06 |
| IMRX | 10%+ Owner | 3,294,173 | $4.24 | $13.97M | -$15.64M | 2 | 2024-04-03 |
| CRBP | 10%+ Owner | 1,475,000 | $9.09 | $13.40M | $70.09M | 2 | 2024-02-06 |
| Ambrx Biopharma Inc. (AMAM) Delisted | 10%+ Owner | 68,714,590 | $28.00 | $1.92B | $78.50M | 1 | 2023-09-19 |
| BMEA | Director | 3,570,872 | $1.25 | $4.46M | $0 | 1 | 2023-06-16 |
| ERAS | Director | 10,813,246 | $18.16 | $196.37M | $8.67M | 3 | 2022-12-21 |
| PYXS | Director | 668,854 | $2.91 | $1.95M | $28.80M | 1 | 2021-10-15 |
| BCAB | Director | 45,841 | $3.53 | $161.8K | $57.60M | 1 | 2020-12-22 |
| OLMA | Director | 3,270,544 | $11.62 | $38.00M | $40.38M | 1 | 2020-11-23 |
| MoonLake Immunotherapeutics (HLXA) Delisted | CEO and Chairman | 430,000 | $13.25 | $5.70M | $4.30M | 1 | 2020-10-22 |
| RNA | Director | 2,214,545 | $11.49 | $25.45M | $21.60M | 1 | 2020-06-18 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 3,122,367 | $76.01 | $237.33M | $14.40M | 3 | 2019-08-12 |
| Axonics, Inc. (AXNX) Delisted | Director | 599,999 | $70.98 | $42.59M | $8.00M | 1 | 2018-11-02 |
| KNSA | Director | 900,443 | $79.44 | $71.53M | $5.00M | 1 | 2018-05-31 |
| KINETA, INC./DE (PTI) Delisted | Director | 189,136 | — | — | $25.62M | 4 | 2016-12-14 |
Recent Filings · Page 2 of 5
45 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-11-06 | DRUG | Buy (P) | +368,662 | $8.00M | EDGAR |
| 2024-10-17 | DRUG | Buy (P) | +1,267,773 | $9.70M | EDGAR |
| 2024-05-08 | EYPT | Buy (P) | +2,550,000 | $30.25M | EDGAR |
| 2024-04-03 | IMRX | Sell (S) | −1,600,000 | -$4.64M | EDGAR |
| 2024-03-18 | IMRX | Sell (S) | −3,636,364 | -$11.00M | EDGAR |
| 2024-02-13 | — | Mixed | +2,909,000 | $29.09M | |
| 2024-02-06 | CRBP | Buy (P) | +2,250,000 | $42.75M | EDGAR |
| 2024-01-30 | CRBP | Buy (P) | +847,896 | $27.34M | EDGAR |
| 2024-01-11 | EYPT | Buy (P) | +2,565,000 | $51.15M | EDGAR |
| 2023-12-12 | EYPT | Buy (P) | +1,764,705 | $30.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.